The France Neuromodulation Market was valued at $271.7 Million in 2025 and projected to reach to $377.6 Million by 2030, representing a compound annual growth rate of 6.8%. France's neuromodulation market is positioned for sustained growth through 2030, supported by favorable demographic trends and robust healthcare infrastructure.
France's neuromodulation market is valued at USD 271.7 million in 2025 and is projected to reach USD 377.6 million by 2030, with a steady CAGR of 6.8%, outpacing many European peers.
France's demographic shift toward an older population is significantly increasing demand for neuromodulation therapies, particularly for chronic pain management, Parkinson's disease, and movement disorders.
Advanced French healthcare systems and strong reimbursement policies from the French National Health Insurance (Assurance Maladie) are facilitating wider adoption of neuromodulation devices and procedures.
Rising incidence of neurological conditions including epilepsy, essential tremor, and depression in France is driving clinical demand for innovative neuromodulation treatment options.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | DEEP BRAIN STIMULATION (Stimulation Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.4% from 2025 to 2030 |
| Largest Segment | INTERNAL NEUROMODULATION (Technology) |
| Market Size Base Year (Billions) | ~USD 6.82 (2025) |
| Revenue Forecast (Billions) | ~USD 10.68 (2030) |
| Segments Covered | Technology, Stimulation Type, Application, End User |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOGEN | United States | Public Company | Internal neuromodulation (implanted SCS/DBS/VNS-aligned adjacencies),External neuromodulation (non-invasive stimulation adjacencies),Spinal cord stimulation–linked care pathways, |
| MEDTRONIC | Ireland | Public Company | Internal neuromodulation – Spinal Cord Stimulation,Internal neuromodulation – Deep Brain Stimulation,Internal neuromodulation – Vagus Nerve and Other Implants, |
| BOSTON SCIENTIFIC CORPORATION | United States | Public Company | Internal neuromodulation systems (implantable SCS, DBS, VNS),External neuromodulation systems and accessories,Radiofrequency and intraosseous nerve ablation for pain, |
| ABBOTT | United States | Public Company | Internal neuromodulation – Spinal cord stimulation,Internal neuromodulation – Deep brain stimulation,Internal neuromodulation – Vagus nerve and other implants, |
| LIVANOVA PLC | United Kingdom | Public Company | Internal Vagus Nerve Stimulation for Epilepsy,Internal Vagus Nerve Stimulation for Depression,Other Neuromodulation (including aura6000 OSA development), |
| NEVRO CORP. | United States | Private Company | Internal SCS systems (Senza, Senza II, Senza Omnia, HFX iQ IPG),Surgical and percutaneous leads,Trial stimulators, remotes, and HFX App / digital, |
| NEUROPACE, INC. | United States | Public Company | Internal neuromodulation – Deep brain–adjacent epilepsy (RNS neurostimulator + leads),Digital platforms and data services (nSight, patient data management, physician tablet ecosystem),Accessories and disposables (non-implantable components, remote monitors, ancillary hardware), |
| BIOVENTUS | United States | Public Company | External / Peripheral Neuromodulation (Stimrouter, TalisMann, Exogen-related pain pathways),Surgical Ultrasonic Systems (neXus, BoneScalpel, SonaStar, SonicOne) in Neuro and Spine,Bone Graft Substitutes and Restorative Therapies in Neuro/Spine Settings, |
| ELECTROCORE, INC. | United States | Public Company | External VNS – gammaCore (migraine, cluster, other headache),General wellness nVNS – Truvaga 350 and Truvaga Plus,Human performance and other non-invasive bioelectronic therapies (TAC-STIM, chronic pain, performance), |
| HELIUS MEDICAL TECHNOLOGIES, INC. | United States | Public Company | External neuromodulation – PoNS for gait and balance deficits,Other neurological wellness and digital programs,Other digital asset / treasury-related activities, |
| NEURONETICS | United States | Public Company | External neuromodulation – TMS for Depression (Clinics & Psychiatrist Offices),External neuromodulation – Hospital-based TMS Programs,Other neuromodulation applications (Ischemia, Epilepsy, Obesity; emerging geographies and pilots), |
| NEUROSIGMA, INC. | United States | Private Company | External Neuromodulation – Trigeminal Nerve Stimulation (eTNS/TNS) for ADHD,External Neuromodulation – TNS for Epilepsy and LGS (early commercialization),External Neuromodulation – TNS for Depression, PTSD, TBI, |
Biogen is a United States-based biotechnology company founded in 1978 with 7,500 employees. Operating as a public company, Biogen focuses on developing and commercializing therapies for neurological and neurodegenerative diseases.
Medtronic is a multinational medical device company headquartered in Ireland, founded in 1949 with 95,000 employees. As a public company, Medtronic develops and manufactures a broad range of medical devices and therapies across multiple therapeutic areas.
Boston Scientific Corporation is a United States-based medical device company founded in 1979 with 59,000 employees. The public company designs, manufactures, and markets medical devices used in interventional medical specialties.
Abbott is a diversified healthcare company founded in the United States in 1888 with 115,000 employees. Operating as a public company, Abbott develops pharmaceuticals, medical devices, diagnostics, and nutritional products.
LivaNova PLC is a United Kingdom-based medical device company founded in 2015 with 3,300 employees. The public company specializes in neuromodulation and cardiac surgery solutions.
Nevro Corp. is a United States-based medical device company founded in 2006 with 1,099 employees. Operating as a private company, Nevro develops neuromodulation therapies for chronic pain management.
NeuroPace, Inc. is a United States-based medical device company founded in 1997 with 220 employees. The public company develops and commercializes neurostimulation technology for neurological disorders.
BioVentus is a United States-based medical device company founded in 2011 with 940 employees. Operating as a public company, BioVentus focuses on orthopedic and regenerative medicine solutions.
ElectroCore, Inc. is a United States-based bioelectronic medicine company founded in 2005 with 83 employees. The public company develops non-invasive vagus nerve stimulation therapies for various conditions.
Helius Medical Technologies, Inc. is a United States-based medical device company with 21 employees. Operating as a public company, Helius develops neurorehabilitation technologies.
Neuronetics is a United States-based medical device company founded in 2001 with 658 employees. The public company develops and commercializes neuromodulation therapies for psychiatric and neurological conditions.
NeuroSigma, Inc. is a United States-based neurotechnology company founded in 2008 with 11 employees. Operating as a private company, NeuroSigma develops bioelectronic therapies for neurological disorders.
France's neuromodulation market is valued at USD 271.7 million in 2025.
France's neuromodulation market is projected to reach USD 377.6 million by 2030.
France's neuromodulation market is expected to grow at a CAGR of 6.8% from 2025 to 2030.
Growth in France is driven by an aging population, increasing neurological disorder prevalence, strong healthcare reimbursement policies, and advancing medical device infrastructure.
France's market is characterized by spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation technologies for pain management, movement disorders, and psychiatric applications.
The study involved key activities in estimating the current market size for the neuromodulation industry. Exhaustive secondary research was conducted to gather information on the neuromodulation sector. The next step was to validate these findings, assumptions, and estimates with industry experts across the value chain through primary research. Different methods, such as top-down and bottom-up approaches, were used to determine the total market size. Subsequently, market segmentation and data triangulation procedures were applied to estimate the market size of segments and subsegments within the neuromodulation market.
The four steps involved in estimating the market size are:
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), , Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global neuromodulation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from various companies and organizations in the neuromodulation market. The primary sources from the demand side include biotechnology companies, CROs, pharmacies, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on important industry trends and key market dynamics.
The following is a breakdown of the primary respondents:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on revenue mapping of major product manufacturers and OEMs active in the worldwide neuromodulation market. All key service providers were identified at the global and/or country/regional level. Revenue mapping for the relevant business segments/sub-segments was performed for the major players. The global neuromodulation market was split into various segments and sub-segments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
The research methodology used to estimate the market size includes the following:

After determining the overall market size using the process described above, the total market was divided into several segments. To finalize the market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were employed where applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Neuromodulation is a medical technology that modifies nerve activity by delivering targeted stimulation to specific areas of the body. It covers a broad range of therapies, from managing chronic pain—which is the most common use—to treating neurological and urological disorders, as well as movement disorders like Parkinson’s disease. By directly affecting neural pathways, neuromodulation can restore function, alleviate symptoms, and enhance quality of life, with ongoing innovations making it a rapidly growing field in modern medicine healthcare.
Full forecast, segment splits, and company analysis for all Neuromodulation Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report